Skip to content

Efficacy and safety of combination 308-nm excimer laser and intralesional corticosteroid versus intralesional corticosteroid monotherapy in the treatment of frontal fibrosing alopecia: a pilot study

Efficacy and safety of combination 308-nm excimer laser and intralesional corticosteroid versus intralesional corticosteroid monotherapy in the treatment of frontal fibrosing alopecia: a pilot study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230816003
Enrollment
6
Registered
2023-08-16
Start date
2018-01-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient with frontal fibrosing alopecia in active form which can diagnosis by has symptom of itching ,burning,pain,redness,scaling, and pustules or diagnosis by skin biopsy excimer laser

Interventions

Patient were treated randomly of sided with 308-nm Excimer Laser combination with intralesional corticosteroid 2 times per week for 12 weeks. Then they were instructed to follow up at every week for 1
308-nm Excimer Laser combination with intralesional corticosteroid,intralesional corticosteroid

Sponsors

Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Age older than 18 years old 2. Patient with frontal fibrosing alopecia in active form which can diagnosis by has symptom of itching ,burning,pain,redness,scaling, and pustules or diagnosis by skin biopsy 3. Patient didn't have any treatment about 1 month before joining the project 4. No pregnancy

Exclusion criteria

Exclusion criteria: 1. Patients which has wound or inflammation at scalp 2. Patients that don't want to join the project

Design outcomes

Primary

MeasureTime frame
Change of Frontal fibrosing alopecia baseline, 12 week after first treatment FFASI index

Secondary

MeasureTime frame
photograph baseline, 4 weeks after first treatment, 8 weeks after first treatment, 12 weeks after first treatment, 4 weeks after last treatment Canon,Clinician assessment baseline, 4 weeks after first treatment, 8 weeks after first treatment, 12 weeks after first treatment, 4 weeks after last treatment global improvement score,Safety 4 weeks after first treatment, 8 weeks after first treatment, 12 weeks after first treatment, 4 weeks after last treatment Adverse events,Patient satisfication 4 weeks after first treatment, 8 weeks after first treatment, 12 weeks after first treatment, 4 weeks after last treatment VAS

Countries

Thailand

Contacts

Public ContactRattapon Thuangtong

Faculty of Medicine Siriraj Hospital, Mahidol University.

rattaponthuangtong@yahoo.com024112722

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026